J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy

25th October 2022 Uncategorised 0

J&J’s BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy
aliu
Tue, 10/25/2022 – 17:10

More: J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy
Source: fierce